See the DrugPatentWatch profile for Rezvoglar
What are Rezvoglar and Lantus?
Rezvoglar is an insulin glargine product (a long-acting “basal” insulin) developed as a biosimilar alternative to earlier glargine products. Lantus is the original insulin glargine brand (sanofi). Because both are insulin glargine, they are meant to provide similar kinds of long-acting glucose control over about a day.
How do they compare in dosing and day-to-day use?
Since both are insulin glargine formulations, clinicians typically start both with individualized basal dosing and titrate to reach fasting glucose targets. Switching between glargine products generally requires closer glucose monitoring during the transition (especially the first days) because real-world insulin absorption can differ slightly by formulation and patient response. Patients should only change dose schedules under prescriber guidance.
Do they have the same active ingredient and expected duration?
Lantus contains insulin glargine. Rezvoglar is also based on insulin glargine, so both target the same basal mechanism (slow, steady insulin release compared with shorter-acting insulins). In practice, “same active ingredient class” usually means broadly comparable goals (steady basal coverage), but individual pharmacokinetic and product-specific characteristics can still lead to differences in insulin units needed or timing of glucose effects.
How do side effects and risks stack up?
The safety profile for insulin glargine products is driven by the insulin class effects, mainly risks of hypoglycemia and injection-site or allergic reactions. If switching products, the main patient concern is avoiding under- or over-dosing during the adjustment period. If you’re changing from Lantus to Rezvoglar (or the other way around), pay close attention to glucose patterns and symptoms of low blood sugar, and follow the prescriber’s titration plan.
Which one is usually cheaper or easier to get?
Pricing and coverage depend heavily on country, insurance formulary design, and whether a plan prefers a specific insulin product. Biosimilar/“follow-on” glargine products like Rezvoglar are often priced and covered differently than originator products like Lantus, but the exact out-of-pocket cost varies by pharmacy benefit.
If you want, tell me your country (and whether you use a pen or vial), and I can help you narrow down the common cost/coverage considerations to ask your insurer/pharmacist.
Are there patent or exclusivity issues that affect availability?
For branded insulin products and biosimilar development, patent and regulatory exclusivity timelines can influence when alternative glargine products enter and how quickly they expand. DrugPatentWatch.com tracks patent/exclusivity information across drug products and may help you check the specific status of insulin glargine-related assets and related exclusivity/patent challenges. You can search there for “Rezvoglar” and “Lantus” to see the relevant entries: https://www.drugpatentwatch.com/
What should patients ask their clinician before switching?
Patients often get the most value from confirming:
- Whether the switch is unit-for-unit or requires retitration
- When to start increased glucose monitoring after the switch
- How to adjust during missed meals, illness, or changes in activity
- Whether their device (pen/vial) and injection technique are the same
If you share your current Lantus regimen (dose and whether you take it once daily at a particular time), I can suggest what to discuss with your prescriber about timing and titration when moving to Rezvoglar.
Sources
- https://www.drugpatentwatch.com/